STRATIFY Lupus comes 10 years after funding for the phase 2 BEAT-LUPUS trial was obtained. The results of that trial were published in 2021 and showed that giving the anti–B-cell activating ...

References 1. FDA approves Benlysta (belimumab) autoinjector for children with systemic lupus erythematosus. News release. GSK. May 20, 2024.

Vesentini, F., et al. (2024). Glucocorticoid withdrawal does not increase the risk of flares during remission in Systemic Lupus Erythematosus. Ann Rheum Dis. DOI: 10.1136/annrheumdis-2024-eular.5032.

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology ...

Topline results were announced from a phase 3 trial evaluating dapirolizumab pegol in patients with moderate to severe systemic lupus erythematosus (SLE). Dapirolizumab pegol is an investigational ...

GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered ...

In a new study, researchers have identified ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) as a novel biomarker that connects allergic rhinitis (AR, commonly known as hay fever), and ...

Descartes-08 for patients with Systemic Lupus Erythematosus Sponsor Name: Cartesian Therapeutics Purpose of Study: This study is being conducted to evaluate the safety, tolerability, and ability to ...

Hydroxychloroquine May Tame Preeclampsia in Lupus Patients Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a Swedish cohort ...

About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).